Announcements Trials
Browse Landscape

Status

Unknown 7Recruiting 7Completed 5Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Gastrointestinal 6Lymphoid 5Tumor-Agnostic 4Thoracic 2Plasma cell 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Multiple Myeloma 130Neoplasms, Plasma Cell 16Recurrence 14Lymphoma 10Neoplasms 9Immunoglobulin Light-chain Amyloidosis 8Monoclonal Gammopathy of Undetermined Significance 5Leukemia, Plasma Cell 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 3Smoldering Multiple Myeloma 3Paraproteinemias 3Leukemia 3Respiratory Aspiration 2Ovarian Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Kidney Neoplasms 2Hypoventilation 2Gastrointestinal Neoplasms 2Disease 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Amyloidosis 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Taste Disorders 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm, Residual × Plasma cell × Clear all
NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

The First Hospital of Jilin University

Not yet recruiting
200 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡